BACKGROUND: End points used to detect influenza in vaccine efficacy trials have varied. Both the inactivated and live attenuated influenza vaccines are efficacious; however, failure to protect occurs. METHODS: We compared characteristics of influenza A (H3N2) and B cases from 3 years of a comparative placebo-controlled trial of inactivated and live attenuated vaccines, and we evaluated the laboratory end points used to determine efficacy. RESULTS: Although illness duration and reported symptoms did not differ by intervention, subjects with influenza in the inactivated vaccine group were less likely than those in the placebo group to report medically attended illnesses. All influenza type A (H3N2) and B cases isolated in cell culture were also identified by real-time polymerase chain reaction (rtPCR). However, only 69% of type A (H3N2) cases identified by rtPCR also were isolated in cell culture. Isolation frequency was lowest among live attenuated vaccine failures, a reflection of lower specimen viral loads. Among cases of rtPCR identified influenza A (H3N2), 90% of placebo and 87% of live attenuated vaccine recipients but only 23% of inactivated vaccine recipients demonstrated serologic confirmation of infection. CONCLUSIONS: In influenza vaccine efficacy studies, virus identification using rtPCR is the ideal end point. Isolation in cell culture will miss cases, and a serologic end point alone will overestimate inactivated vaccine efficacy.
RCT Entities:
BACKGROUND: End points used to detect influenza in vaccine efficacy trials have varied. Both the inactivated and live attenuated influenza vaccines are efficacious; however, failure to protect occurs. METHODS: We compared characteristics of influenza A (H3N2) and B cases from 3 years of a comparative placebo-controlled trial of inactivated and live attenuated vaccines, and we evaluated the laboratory end points used to determine efficacy. RESULTS: Although illness duration and reported symptoms did not differ by intervention, subjects with influenza in the inactivated vaccine group were less likely than those in the placebo group to report medically attended illnesses. All influenza type A (H3N2) and B cases isolated in cell culture were also identified by real-time polymerase chain reaction (rtPCR). However, only 69% of type A (H3N2) cases identified by rtPCR also were isolated in cell culture. Isolation frequency was lowest among live attenuated vaccine failures, a reflection of lower specimen viral loads. Among cases of rtPCR identified influenza A (H3N2), 90% of placebo and 87% of live attenuated vaccine recipients but only 23% of inactivated vaccine recipients demonstrated serologic confirmation of infection. CONCLUSIONS: In influenza vaccine efficacy studies, virus identification using rtPCR is the ideal end point. Isolation in cell culture will miss cases, and a serologic end point alone will overestimate inactivated vaccine efficacy.
Authors: R B Belshe; W C Gruber; P M Mendelman; I Cho; K Reisinger; S L Block; J Wittes; D Iacuzio; P Piedra; J Treanor; J King; K Kotloff; D I Bernstein; F G Hayden; K Zangwill; L Yan; M Wolff Journal: J Pediatr Date: 2000-02 Impact factor: 4.406
Authors: Gabriel M Leung; Joseph S M Peiris; Benjamin J Cowling; Kwok Hung Chan; Vicky J Fang; Lincoln L H Lau; Hau Chi So; Rita O P Fung; Edward S K Ma; Alfred S K Kwong; Chi-Wai Chan; Wendy W S Tsui; Ho-Yin Ngai; Daniel W S Chu; Paco W Y Lee; Ming-Chee Chiu Journal: N Engl J Med Date: 2010-06-10 Impact factor: 91.245
Authors: J J Treanor; F G Hayden; P S Vrooman; R Barbarash; R Bettis; D Riff; S Singh; N Kinnersley; P Ward; R G Mills Journal: JAMA Date: 2000-02-23 Impact factor: 56.272
Authors: L G Rudenko; A N Slepushkin; A S Monto; A P Kendal; E P Grigorieva; E P Burtseva; A R Rekstin; A L Beljaev; V E Bragina; N Cox Journal: J Infect Dis Date: 1993-10 Impact factor: 5.226
Authors: Joshua G Petrie; Caroline Cheng; Ryan E Malosh; Jeffrey J VanWormer; Brendan Flannery; Richard K Zimmerman; Manjusha Gaglani; Michael L Jackson; Jennifer P King; Mary Patricia Nowalk; Joyce Benoit; Anne Robertson; Swathi N Thaker; Arnold S Monto; Suzanne E Ohmit Journal: Clin Infect Dis Date: 2015-11-12 Impact factor: 9.079
Authors: Sophia Ng; Vicky J Fang; Dennis K M Ip; Kwok-Hung Chan; Gabriel M Leung; J S Malik Peiris; Benjamin J Cowling Journal: J Infect Dis Date: 2013-08-01 Impact factor: 5.226
Authors: Robert M Jacobson; Diane E Grill; Ann L Oberg; Pritish K Tosh; Inna G Ovsyannikova; Gregory A Poland Journal: Hum Vaccin Immunother Date: 2015 Impact factor: 3.452
Authors: Peter H Goff; Tomoko Hayashi; Luis Martínez-Gil; Maripat Corr; Brian Crain; Shiyin Yao; Howard B Cottam; Michael Chan; Irene Ramos; Dirk Eggink; Mitra Heshmati; Florian Krammer; Karen Messer; Minya Pu; Ana Fernandez-Sesma; Peter Palese; Dennis A Carson Journal: J Virol Date: 2015-01-07 Impact factor: 5.103
Authors: Carlos G Grijalva; Yuwei Zhu; Derek J Williams; Wesley H Self; Krow Ampofo; Andrew T Pavia; Chris R Stockmann; Jonathan McCullers; Sandra R Arnold; Richard G Wunderink; Evan J Anderson; Stephen Lindstrom; Alicia M Fry; Ivo M Foppa; Lyn Finelli; Anna M Bramley; Seema Jain; Marie R Griffin; Kathryn M Edwards Journal: JAMA Date: 2015-10-13 Impact factor: 56.272
Authors: G Freeman; R A P M Perera; E Ngan; V J Fang; S Cauchemez; D K M Ip; J S M Peiris; B J Cowling Journal: Epidemiol Infect Date: 2016-03-28 Impact factor: 2.451
Authors: Tim K Tsang; Vicky J Fang; Ranawaka A P M Perera; Dennis K M Ip; Gabriel M Leung; J S Malik Peiris; Simon Cauchemez; Benjamin J Cowling Journal: Epidemiology Date: 2016-01 Impact factor: 4.822